Integrative analysis identifies IL-6/JUN/MMP-9 pathway destroyed blood-brain-barrier in autism mice via machine learning and bioinformatic analysis.

Scientists studied how inflammation might damage the protective barrier around the brain in autism. Using computer analysis and mouse studies, they found that certain inflammatory molecules (IL-6, JUN, MMP-9) work together to weaken this brain barrier. When they blocked one part of this process with a drug, the harmful effects were reduced. This research is still in early stages using animal models, but it may help scientists understand how inflammation contributes to autism and identify potential future treatments.

This preclinical study used machine learning and bioinformatics to identify molecular pathways linking blood-brain barrier dysfunction to autism pathogenesis. Researchers analyzed gene expression data and identified JUN as a key regulatory gene. Using a maternal immune activation mouse model of autism, they found decreased tight junction proteins (ZO-1, occludin) indicating compromised blood-brain barrier integrity. The study revealed the IL-6/JUN/MMP-9 pathway as a specific mediator of barrier dysfunction, with elevated IL-6 and MMP-9 expression confirmed in autism mice.

Pharmacological intervention with JNK inhibitor successfully downregulated JUN and MMP-9 expression both in vivo and in vitro using microglial cell cultures. These findings suggest the IL-6/JUN/MMP-9 pathway represents a potential therapeutic target for addressing neuroinflammation-related autism symptoms.

Identifies IL-6/JUN/MMP-9 pathway as potential therapeutic target for autism-related neuroinflammation. JNK inhibitors may warrant investigation as interventions for blood-brain barrier dysfunction in autism. Findings support neuroinflammation as contributing factor in autism pathogenesis, though human studies needed before clinical translation.

Study conducted only in animal models and cell cultures. Human applicability unclear. Sample sizes not reported. Single study findings require replication. Maternal immune activation model may not represent all autism etiologies.

Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by social communication deficits and restricted, repetitive behaviors. Growing evidence implicates neuroinflammation-induced blood-brain barrier (BBB) dysfunction as a key pathogenic mechanism in ASD, although the underlying molecular pathways remain poorly understood. This study aimed to identify critical genes linking BBB function and neuroinflammatory activation, with the ultimate goal of evaluating potential therapeutic targets. Through integrative analysis combining differential gene expression profiling with three machine learning algorithms - Least Absolute Shrinkage and Selection Operator (LASSO) regression, Support Vector Machine Recursive Feature Elimination (SVM-RFE), and RandomForest combined with eXtreme Gradient Boosting (XGBoost) - we identified four hub genes, with JUN emerging as a core regulator.

JUN demonstrated strong associations with both BBB integrity and microglial activation in ASD pathogenesis. Using a maternal immune activation (MIA) mouse model of ASD, we observed significant downregulation of cortical tight junction proteins ZO-1 and occludin, confirmed through immunofluorescence and qPCR analysis. Bioinformatics analysis revealed a close correlation between JUN and IL-6/MMP-9 signaling in ASD-associated microglial activation. These findings were validated in vivo, with immunofluorescence and qPCR demonstrating elevated IL-6 and MMP-9 expression in ASD mice.

Pharmacological intervention using ventricular JNK inhibitor administration effectively downregulated JUN and MMP-9 expression. In vitro studies using IL-6-stimulated BV-2 microglial cells replicated these findings, showing JNK inhibitor-mediated suppression of JUN and MMP-9 upregulation. These results collectively identify the IL-6/JUN/MMP-9 pathway as a specific mediator of barrier dysfunction in ASD, representing a promising target for personalized therapeutic interventions.